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Take-home message: Our study describes characteristics and in-hospital mortality of the largest 
population of COVID-19 patients treated with CPAP outside ICU. Treatment duration for patients 
failing CPAP prior to intubation represents a risk factor for mortality.  
  
Abstract 
Aim We aim at characterizing a large population of Coronavirus 19 (COVID-19) patients with 
moderate-to-severe hypoxemic acute respiratory failure (ARF) receiving CPAP outside intensive care 
unit (ICU), and ascertaining whether the duration of CPAP application increased the risk of mortality for 
patients requiring intubation. 
Methods In this retrospective, multicentre cohort study, we included COVID-19 adult patients, treated 
with CPAP outside ICU for hypoxemic ARF from March 1
st
 to April 15
th
, 2020. We collected 
demographic and clinical data, including CPAP therapeutic goal, hospital length of stay (LOS), and 60-
day in-hospital mortality. 
Results The study includes 537 patients with a median age of 69 (IQR, 60-76) years. Males were 391 
(73%). According to predefined CPAP therapeutic goal, 397 (74%) patients were included in full 
treatment subgroup, and 140 (26%) in the do-not intubate (DNI) subgroup. Median CPAP duration was 
4 (IQR, 1-8) days, while hospital LOS 16 (IQR, 9-27) days. Sixty-day in-hospital mortality was overall 
34% (95%CI, 0.304-0.384), and 21% (95%CI, 0.169-0.249) and 73% (95%CI, 0.648-0.787) for full 
treatment and DNI subgroups, respectively. In the full treatment subgroup, in-hospital mortality was 
42% (95%CI, 0.345-0.488) for 180 (45%) CPAP failures requiring intubation, while 2% (95%CI, 0.008-
0.035) for the remaining 217 (55%) patients who succeeded. Delaying intubation was associated with 
increased mortality [HR, 1.093 (95%CI, 1.010-1.184)]. 
Conclusions We described a large population of COVID-19 patients treated with CPAP outside ICU. 
Intubation delay represents a risk factor for mortality. Further investigation is needed for early 




Noninvasive ventilation (NIV) administered as bi-level positive airway pressure (BiPAP) or continuous 
positive airway pressure (CPAP) is commonly used in various critical care settings across a variety of 
aetiologies of acute respiratory failure (ARF). For hypercapnic ARF, mainly consequent to chronic 
obstructive pulmonary disease exacerbation, BiPAP can be used at an early stage to prevent intubation, 
at a later stage as alternative to first-line endotracheal intubation, or as a mean to facilitate weaning [1]. 
For hypoxemic ARF, recommendations strongly support the use of both BiPAP and CPAP in patients 
with episodes of cardiogenic pulmonary edema [2,1], while fewer data suggest their use in 
immunosuppressed [3,1] and in post-operative [4,1] patients. In patients with de novo hypoxemic ARF 
evidences and recommendations on the use of NIV are still to be determined [1]. Moreover, the 
application of NIV in patients with acute respiratory distress syndrome (ARDS) complicating viral 
pneumonia is controversial [5]. 
During coronavirus disease 2019 (COVID-19) pandemic, Piedmont together with Lombardy, Emilia-
Romagna and Veneto was one of the most affected Italian regions. Due to the exceptional demand on 
intensive care unit (ICU) resources, hospitals increased the number of ICU beds and converted many 
general wards in respiratory intermediate care units (RICU) to treat patients with severe pneumonia and 
ARDS-needing respiratory support and monitoring. Indeed, NIV in patients with different therapeutic 
indications i.e., full-treatment and do-not-intubate [6] has been shown to be successfully applicable also 
outside the ICU [7,8], when appropriate monitored setting and trained personnel are employed. 
Data on NIV during COVID-19 pandemic, so far, consider predominantly patients admitted to the ICU 
[9,10,11,12,13]. The rate of patients receiving NIV at ICU admission ranges from 11%, as reported by 
an Italian multicentre investigation [10], to 56% according to a Chinese single centre study [11]. 
Exposure to noninvasive forms of respiratory support might have been even more diffuse outside ICU, 
though only data from two monocentre studies are presently available, accounting overall for 40 
patients, 38 treated with CPAP [14] and two with NIV or high flow oxygen therapy [15]. 
We designed this retrospective multicentre study to describe the clinical characteristics of patients with 
laboratory-confirmed COVID-19 treated with CPAP outside ICU, to assess 60-day in-hospital mortality, 
and hospital length of stay (LOS), and to ascertain whether the duration CPAP application prior to 





This is a multicentre, retrospective observational study performed in six hospitals from the area of 
Eastern Piedmont in Northern Italy. All the participating centres obtained ethic committee approval. 
More details on study design and ethics approval are provided in the supplementary material. 
Patient enrolment and data collection 
All patients admitted to one of the participating hospitals from March 1
st
 to April 15
th
 2020 with 
hypoxemic ARF secondary to confirmed SARS-CoV-2. Inclusion criteria were: 1) age ≥18 years, 2) 
respiratory distress and partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 200 
mmHg during Venturi mask oxygen therapy, 3) CPAP initiation outside ICU. Patients who received 
post-extubation CPAP were excluded. 
Patients were classified according to predefined CPAP therapeutic goal applied by the medical team, in 
two subgroups [6]: 1) full treatment, i.e. patients scheduled to receive intubation in the case of CPAP 
failure; and 2) do-not-intubate (DNI), when CPAP was ceiling of treatment. In case patient changed the 
therapeutic goal during hospital stay, the last CPAP goal has been considered. The therapeutic goal of 
CPAP was collegially discussed within the multidisciplinary teams, with the patients and with the 
families, taking into account comorbidities [16], quality of life and patient wishes. Possible 
discrepancies between patients and relatives were solved through additional discussions between patient, 
relatives, and the medical team. 
Demographic characteristics, body mass index (BMI), blood sample exams performed at hospital 
entrance (white blood cell count, lymphocytes count, creatinine, alanine transaminase, aspartate 
transaminase, lactate dehydrogenase, C-reactive protein, D-dimer, ferritin), arterial blood gas (ABG) 
values obtained prior to CPAP initiation and 2 to 24 hours after; and coexisting comorbidities were also 
recorded. Charlson Comorbidity Index (CCI)[17] was also computed on the first day of hospital 
admission. This index contemplates 17 categories of comorbidity recorded via anamnesis. Age is not 
included as comorbidity in the CCI version adopted. Finally, we collected data about the clinical 
outcomes such as duration of CPAP use, hospital length of stay (LOS), intubation and hospital mortality. 
For patients still in the hospital on May 15
th
 (n=32), the outcomes have been censored on that day.  
CPAP and RICU organization 
Details on CPAP setting, schedule, RICU organization and criteria for intubation are described in the 
supplementary material. 
Statistical analysis 
Descriptive statistics are used to summarize the main demographic characteristics and the results of 
laboratory findings of all patients included in the study. Categorical variables are reported as absolute 
frequencies and percentages, while numerical variables as median and interquartile range (IQR). The 
frequency and percentage of missing values for all variables is also reported. Mann Whitney U test is 
used to assess the difference between two independent samples, while Wilcoxon signed-rank test for 
repeated measurements. Chi-square statistic is used for testing relationships of categorical variables.  
Curves of cumulative incidence of in-hospital mortality are drawn to describe mortality along 60 days, 
either overall and stratified for treatment goal, and in the full treatment subgroup separately for patients 
succeeding CPAP or receiving intubation. 
In order to avoid immortal time bias, in the survival analysis of patients receiving intubation, 
observation period started at the day of intubation. In the other analyses, observation period started at the 
day of CPAP initiation. Since discharge must be considered an informative censoring [18], cumulative 
incidence was calculated using methods accounting for competing risk. To evaluate the cumulative 
incidence of in-hospital mortality for patients not undergoing intubation, all full treatment subjects are 
considered, and intubation is treated as a competing event allowing to account for the contribution of the 
time spent by intubated patients on CPAP. The Gray’s test is used to assess the difference between 
cumulative incidence functions. Fine and Gray multivariate competing risk model is adopted to calculate 
the sub-distribution hazard ratios (sHR) and the corresponding 95% confidence intervals (95%CI) for 
the association between CPAP duration and in-hospital mortality risk in intubated patients, considering 
discharge as competing event. In the main analyses, missing data are managed by listwise deletion. We 
also carried out a secondary analysis using multiple imputation to evaluate the impact of missing values 
on the association estimates. Missing imputation is performed using the Expectation-Maximization 
algorithm (500 imputations) and considering the “missing at random” mechanism. More details about 
the model are provided in the supplementary material. 
All hypothesis tests are two-tailed and a significance level of 0.05 is considered. All statistical analysis 
was performed using STATA (Stata Statistical Software: Release 15. College Station, TX, USA: 











 to April 15
th
, a total of 2845 patients with confirmed COVID-19 were admitted to the six 
hospitals of the eastern Piedmont (Figure 1s). Of these, 326 (11%) patients were treated in ICU, 31 (1%) 
and 295 (10%) with noninvasive and invasive mechanical ventilation, respectively. CPAP was applied to 
537 (22%) patients in RICU.  
Table 1 shows the demographic and clinical patients’ characteristics. The number of observations for 
each variable is displayed in table 1s. The median age was 69 (IQR, 60-76) years, and BMI 28 (IQR, 25-
31) kg/m
2
. Males were 391 (73%). Laboratory values at hospital entrance are also summarized in table 
1. Median white blood cell count was 6.9 (IQR, 5.1-9.5) x 10
3
/µL, with lymphopenia, i.e., 0.8 (0.6–1.1) 
x 10
3
/µL. Median values of creatinine, aspartate-aminotransferase, alanine-aminotransferase were in the 
normal range, while C-reactive protein, ferritin, lactate dehydrogenase and D-dimer were all above the 
normal range. CCI median value was 1 (IQR, 0-2), chronic arterial hypertension was present in 278 
(52%) patients, diabetes in 138 (26%) patients, and ischaemic heart disease in 66 (12%) patients.  
The most common interface was the helmet, in 399 (74%) patients, while face masks were used in 123 
patients (23%); 15 patients (3%) alternated both interfaces. Median CPAP duration was 4 (IQR, 1-8) 
days. Overall cumulative 60-day in-hospital mortality was 34% (cumulative incidence, 0.344, 95%CI, 
0.304-0.384), as depicted in Figure 1A, while hospital LOS was 16 (IQR, 9-27) days.  
Demographic and clinical patients’ characteristics stratified by PaO2/FiO2 performed 2 to 24 hours after 
CPAP initiation and interface applied, are provided in the supplementary material in table 2s and 3s, 
respectively. Overall cumulative 60-day in-hospital mortality stratified according to PaO2/FiO2 and 
interface applied is also depicted in Figure 2s A and B, in the supplementary material. As expected, 
mortality seemed to increase in patients with lower PaO2/FiO2, while was not different between patients 
treated with helmet (cumulative incidence, 0.315, 95%CI, 0.270-0.361) or face mask (cumulative 
incidence, 0.407, 95%CI, 0.320-0.493), p= 0.094. 
When dividing patients according to the therapeutic goal (table 2), patients in the full treatment subgroup 
were younger [median, 66 (IQR, 57-72) years] compared to DNI [median, 79 (IQR, 72-84) year]. DNI 
subgroup had higher D-dimer values than full treatment patients [median, 1351 (IQR, 637-3518) 
µgFEU/L vs. 897 (IQR, 496-1665) µgFEU/L] (p=0.02), and greater CCI [median, 2 (IQR, 1-3) vs. 
median, 0 (IQR, 0-1)] (p<0.0001). The number of observations for each variable is displayed in table 4s. 
Table 5s shows ABGs and table 6s the number of observations for each variable. While the first ABG 
indicated in table 5s was performed 1-day (IQR, 0-3 days) after hospital admission, the second was 
performed 2 to 24 hours after CPAP initiation.  
Before starting CPAP, patients presented a PaO2/FiO2 of 108 (IQR, 71-157) mmHg and a respiratory 
rate of 27 (IQR, 22-32) breaths/min. Soon after CPAP, PaO2/FiO2 raised to 157 (IQR, 109-255) mmHg 
and respiratory rate decreased to 24 (IQR, 20-28) breaths/min with median CPAP of 10 (IQR, 10-12) 
cmH2O, and FiO2 of 50% (IQR, 50-60%). Median CPAP duration was 4 days for both subgroups, while 
hospital LOS was 19 (IQR, 11-30) days for full treatment and 11 (IQR, 6-20) days for DNI subgroup. 
Figure 1B depicts 60-day in-hospital mortality for full-treatment [21% (cumulative incidence 0.208, 
95%CI, 0.169-0.249)] and DNI [73% (cumulative incidence 0.731, 95%CI, 0.648-0.787)], (p < 0.0001). 
Within the full treatment subgroup, 60-day in-hospital mortality was 42% (cumulative incidence 0.418, 
95%CI, 0.345-0.488) for patients receiving intubation (Figure 2), and 2% (cumulative incidence 0.018, 
95%CI, 0.008-0.035) for patients succeeding CPAP (Figure 3s).  
CPAP duration was 2 days (IQR, 1-3 days) in patients who survived and 3 days (IQR. 1-5 days) in 
patients who died (p=0.061). Table 3 shows that duration of CPAP application was an independent 
predictor of mortality for patients requiring intubation. The model, adjusting for age, gender, 
comorbidities, LDH, C-reactive protein values, and lymphocyte count, indicates a 9.3% [HR, 1.094 
(95%CI, 1.010-1.184)] increase of the risk of death for each day of treatment. The association between 
duration of CPAP and mortality does not substantially change in the secondary analysis using multiple 
imputation [HR, 1.060 (95%CI, 1.001-1.121)], as presented in Table 7s. 60-day in-hospital mortality 
was significantly higher in patients subjected to CPAP for more than 3 days (cumulative incidence 
0.510, 95%CI, 0.393-0.615) as compared to those receiving CPAP for 3 days or less (cumulative 
incidence 0.350, 95%CI, 0.259-0.441), as shown in Figure 4s. 
  
Discussion 
This multicentre retrospective observational study on 537 patients hypoxemic ARF secondary to 
laboratory-confirmed COVID-19 infection, shows that CPAP applied to different therapeutic goals i.e., 
candidate to intubation in the case of CPAP failure and do-not-intubate in which CPAP is considered the 
ceiling of treatment, is feasible outside ICU. Treatment duration for patients failing CPAP prior to 
intubation represents a risk factor for mortality. 
CPAP can be delivered both in ICU and outside ICU.  Grasselli et al. [10], found that 11% of the 
patients entering ICU needed NIV, while early data from China revealed a higher percentage i.e., 41.7% 
[13], 43.3% [19], 56% [11], 62%[15]. In keeping with data by Grasselli et al. [10], as CPAP was 
delivered to 31 out of 326 patients (9.5%) entering ICU. 
Data on the use of CPAP in COVID-19 patients treated outside ICU are scarce. Two over 28 patients 
(7%) received NIV or HFNC outside ICU in a single centre study in Wuhan [15]. Oranger et al., treated 
38 patients with CPAP in a respiratory ward [14]. Although the study included a limited  patients’ 
number, CPAP resulted to be feasible and the authors also suggest a potential benefit for both full 
treatment and DNI patients, as opposed to those treated with oxygen only [14].  
As far as mortality concerns, we showed an overall cumulative 60-day in-hospital mortality of 34% in 
patients with moderate to severe forms of ARF COVID-19-related needing CPAP. The rate of mortality 
observed in our study, is not divergent from those reported in several prior studies [9,10,15,12,13] for 
ICU patients, predominantly intubated, which varied from 17% [13] to 67% [9]. 
Lastly, our study includes 26% of DNI patients, for whom CPAP was considered ceiling of treatment. 
Rate of DNI patients reported in our study is similar to 15% observed in  a small cohort of  patients 
treated outside ICU during COVID-19 pandemic [14],  i.e., as well as to 30% reported by a large Italian 
multicentre observational study in patients with pneumonia non-COVID-19 related, treated with NIV 
outside ICU [20]. In our study, 60-day in-hospital mortality for DNI patients was 73%. 
A major concern when treating patients with hypoxemic ARF with NIV, is related to NIV-failure rate 
that might occur in up 50% of the cases with consequent recourse to intubation [21]. Undue prolongation 
of NIV may worsen lung injury resulting in the so-called patient self-inflicted lung injury [22], while the 
direct consequence of NIV failure is delaying intubation and adequate treatment with invasive 
ventilation [23,1]. Our data confirm that intubation delay for those requiring afterward invasive ventilation 
is associated with increased risk for mortality. In other pandemics, such as influenza, H1N1, and severe 
acute respiratory syndrome (SARS), NIV failure ranges from 10 to more than 70% [24], reaching 90% 
with middle east respiratory syndrome [25]. In our study, CPAP failure rate was 45%, which indicates 
that effective treatment occurred in more than half of patients, who avoided invasive ventilation through 
an endotracheal tube, which is a life-saving procedure, but it is also prone to several side-effects and 
complications [26]. 
Limitations 
The study has several limitations. First, we were not able to compare our population with an historical 
control.  Second, most of data have been retrospectively derived from the medical records. According to 
the retrospective nature of the study, formal criteria to start CPAP treatment were not defined a priori , 
and the time span between CPAP initiation and control ABG was relatively long. Third, definitions of 
full treatment and DNI patients, although internationally accepted [6], are influenced by patients, 
families, and clinicians thinking and might be influenced by cultural, religious and geographical factors. 
Fourth, due to the diversity of interfaces and devices used in our study, the actual applied pressure could  
somewhat differ from the preset value [27]. Fifth, due to the number of missing data among many 
important variables such as D-Dimer and respiratory rate, we were not able introduce them in the model 
that explore the correlation between CPAP duration and mortality. Lastly, because of the exceptionality 
of pandemic outbreak, our results are not generalizable to other conditions.  
Conclusions 
To the best of our knowledge, this is the largest retrospective cohort study on patients with COVID-19 
treated with CPAP outside ICU. We show that CPAP is feasible outside ICU with overall in-hospital 
mortality similar to that reported in other studies treating critically ill ICU patients. In-hospital mortality 
is closely related to the therapeutic goal, patients having DNI order being affected by much higher 
mortality. Intubation delay is confirmed to be an independent risk factor for mortality. Further studies 
are necessary to ascertain the potential infective risk related to CPAP treatment outside ICU among 
healthcare workers. 
  















































Values are median (interquartile range) or number (percentage). 
CPAP, noninvasive continuous positive airway pressure; ICU, intensive care unit; 
FEU, fibrinogen-equivalent unit
 Overall (n=537) 
Characteristics  
Age, years 69 (60-76) 
Male, n (%) 391 (73) 
Body mass index, kg/m
2
 28 (25-31) 
White blood cell count, x10
3
/L 6.9 (5.1-9.5) 
Lymphocyte count, x10
3
/L 0.8 (0.6-1.1) 
Creatinine, mg/dL 1.0 (0.8-1.3) 
Aspartate-aminotransferase, U/L 41 (29-59) 
Alanine-aminotransferase, U/L 31 (22-50) 
C-reactive protein, mg/dL 11 (6-17) 
Ferritin, ng/mL 1053 (565-1643) 
Lactate dehydrogenase, U/L 560 (410-786) 




Chronic arterial hypertension, n (%) 278 (52) 
Diabetes, n (%) 138 (26) 





















































Values reported as median (interquartile range) or number (percentage). p values were calculated by Mann-Whitney U test or χ
2
 test, as appropriate 
 Full treatment (n=397) Do not intubate (n=140) p value 
Characteristics    
Age, years 66 (57-72) 79 (72-84) < 0.0001 
Male, n (%) 293 (74) 98 (70) 0.22 
Body mass index, kg/m
2
 28 (25-31) 28 (25-31) 0.74 
White blood cell count, x10
3
/L 6.8 (5.1-9.1) 7.1 (5.0-10.6) 0.47 
Lymphocyte count, x10
3
/L 0.8 (0.6-1.1) 0.7 (0.5-1.1) 0.04 
Creatinine, mg/dL 0.9 (0.8-1.2) 1.2 (0.9-1.5) < 0.0001 
Aspartate-aminotransferase, U/L 42 (31-59) 39 (26-60) 0.36 
Alanine-aminotransferase, U/L 34 (24-53) 25 (19-39) < 0.0001 
C-reactive protein, mg/dL 11 (6-17) 12 (7-18) 0.26 
Ferritin, ng/mL 1068 (600-1674) 817 (411-1389) 0.08 
Lactate dehydrogenase, U/L 575 (415-786) 538 (393-760) 0.47 
D-dimer, gFEU/L 897 (496-1665) 1351 (637-3518) 0.02 
Charlson comorbidity index
 
0 (0-1) 2 (1-3) < 0.0001 
Chronic arterial hypertension, n (%) 199 (50) 79 (56) 0.12 
Diabetes, n (%) 94 (24) 44 (31) 0.047 
Ischaemic heart disease, n (%) 37 (9) 29 (21) 0.001 
CPAP, days
 
4 (2-9) 4 (1-8) 0.33 
Hospital length of stay, days
 
19 (11-30) 11 (6-20) < 0.0001 
CPAP, noninvasive continuous positive airway pressure; FEU, fibrinogen-equivalent unit
 
 
Table 3 Fine and Gray model for the association 
between CPAP duration and mortality 
 
sHR 95%CI 
CPAP, days 1.094 (1.010-1.184) 
Male 1.596 (0.814-3.129) 
Age 1.023 (0.985-1.064) 
Hypertension, yes vs. no 1.224 (0.729-2.056) 
Charlson index 1.392 (1.145-1.693) 
Lactate dehydrogenase, U/L 1.001 (1.000-1.002) 
C-reactive protein, mg/dL 0.983 (0.947-1.020) 
Lymphocytes, x10
3
/mL 1.269 (0.699-2.302) 
CPAP, noninvasive continuous positive airway pressure; 
sHR, sub-distribution hazard ratio; 95% CI, 95% 
confidence interval. 
Sub-distribution hazard ratio and 95% corresponding 
confidence interval deriving from the multivariate Fine 








Fig. 1 Cumulative incidence of in-hospital mortality in the overall patients (Panel A) and stratified 
by treatment (Panel B) i.e., DNI and full treatment patients in grey and in black lines, respectively. 
Curves and corresponding 95% confidence intervals (dashed lines). 
CPAP, noninvasive continuous positive airway pressure; DNI, do not intubate. 
Fig. 2 Cumulative incidence of in-hospital mortality in patients requiring invasive mechanical 
ventilation. Curve and corresponding 95% confidence interval (dashed lines). 
ETI, endo-tracheal intubation. 
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Outcomes of COVID-19 patients treated with continuous positive airway pressure outside ICU 
Supplementary material 
Study Design 
This was a multicentre, retrospective observational study performed in six hospitals of the eastern 
Piedmont region, Northern Italy i.e., “Maggiore della Carità” University hospital in Novara, “SS. 
Antonio Biagio e Cesare Arrigo”, hospital in Alessandria, “S. Andrea” hospital in Vercelli, “VCO 
ASL” in Domodossola, “Nuovo Ospedale degli Infermi” hospital in Biella. One centre i.e., 
“Maggiore della Carità” University hospital in Novara, enrolled patients prospectively n=138 
patients, as the protocol for the data collection, has been approved on the 07
th
 June 2019 (CE 64/19) 
for a study, monitoring patients treated with CPAP outside ICU. 
All the participating centres obtained ethics committee approval for the present research project (CE 
87/20; CE 112/20, CE 111/20, CE 110/20, ASO.RianGen.20.02, AslVC.RianGen.20.01). Informed 
consent was obtained for all the patients prospectively enrolled and for those still in the hospital 
after ethics committee protocol approval, while for the others, ethics committee waived the need for 
informed consent. Local investigators were responsible for ensuring data integrity and validity.  
Criteria for intubation 
Criteria for intubation were cardiac or respiratory arrest; inability to protect the airway; coma or 
psychomotor agitation; unmanageable secretions or uncontrolled vomiting; life threatening 
arrhythmias or electrocardiographic signs of ischemia; hemodynamic instability defined as systolic 
arterial pressure < 90 mmHg despite adequate filling or use of vasoactive agents; intolerance to all 
interfaces; dyspnoea during noninvasive continuous positive airway pressure (CPAP), respiratory 
rate >30 breaths/min; peripheral oxygen saturation (SpO2) below 92% during CPAP, acidosis with a 





CPAP was delivered through helmets (Intersurgical, Mirandola (MO), Italy; Dimar, Medolla, MO, 
Italy) and face masks (Intersurgical, Mirandola, MO, Italy; Dimar, Medolla, MO, Italy; 
Fisher&Paykel, Auckland, New Zealand; ResMed, San Diego, CA, USA; Philips Respironics, 
Murrysville, PA, USA) via Boussignac systems or via flow-meters (typically 30-50 l/min 
depending on the interface chosen) with a scale that allowed the clinician to regulate oxygen and air 
flow separately to set inspiratory oxygen fraction (FiO2). Bacterial and viral filter was applied to the 
expiratory port. CPAP was set between 10 and 12 cmH2O according to patient’s needs, tolerance 
and any side-effects. CPAP pressure could be increased up to 15 cmH2O. CPAP was delivered on 
an as-needed basis. When respiratory parameters improved, CPAP support was gradually reduced 
with a progressive increase of time off CPAP, until discontinuation. 
Respiratory intermediate care unit organization 
Nurse to patient ratios varied from a maximum of 1:6 both during day and night to a minimum of 
1:8 and 1:12, respectively during days and nights. In three hospitals, medical staff treating CPAP 
COVID-19 patients was an ad-hoc mixed team, mainly internists, pneumologists, emergency 
physicians, cardiologists, anaesthesiologists/ICU physicians, while in the other three hospitals the 
medical team was the same as before COVID-19 pandemic. CPAP was prescribed mainly by 
anaesthesiologists actively working with the ad-hoc COVID-19 ward team, but also by 
pneumologists and emergency doctors or by consulting anaesthesiologists. Personnel was 
adequately trained for NIV; those who were not, received a short-organized training during 
pandemic. Ward monitoring included SpO2, non-invasive blood pressure, ECG applied 
continuously or at a defined time point depending on the severity of the patient. Blood gas analysis 
was performed when clinically relevant. Patients received daily visit from the consulting physician 
who prescribed CPAP if not present in the ad-hoc ward team.  
 
Statistical analysis 
Fine and Gray model included as adjustment age, gender, comorbidities i.e., Charlson comorbidity 
index and hypertension, LDH, C-reactive protein levels and lymphocyte count. The model was 
further adjusted by centre. The adjustment variables were selected on the base of their clinical 













Figure 1S Study flow chart 
COVID-19, coronavirus disease 19; iMV, invasive mechanical ventilation; ICU, intensive care unit; NIV, noninvasive 
ventilation; CPAP, noninvasive continuous positive airway pressure. 
             




















2845 COVID-19 patients admitted to 






537 CPAP outside ICU 
116 iMV in ICU 
31 NIV in ICU 
2161 received no oxygen, low or high 
flow oxygen therapy 
180 iMV in ICU 
 
Figure 2S Cumulative incidence of in-hospital mortality stratified by PaO2/FiO2 levels (Panel A) and interface 






Cumulative incidence at 60 days – PaO2/FiO2≤100: 0.558 (0.448-0.654). 
Cumulative incidence at 60 days – PaO2/FiO2 (100-200]: 0329 (0.264-0.395). 
Cumulative incidence at 60 days – PaO2/FiO2 (200-300]: 0.280 (0.183-0.385). 
Cumulative incidence at 60 days – PaO2/FiO2>300: 0.100 (0.045-0.172). 
P-value Grey’s test for equality of CIF <0.0001 
 
CPAP device 
Cumulative incidence at 60 days – CPAP  Helmet: 0.315 (0.270-0.361). 
Cumulative incidence at 60 days – CPAP  Mask: 0.407 (0.320-0.493). 








Figure 3S Cumulative incidence of in-hospital mortality in full treatment patients not requiring 































Curves and corresponding 95% confidence intervals (dashed lines). 
Cumulative incidence at 60 days 0.018 (0.008-0.035). 
CPAP, noninvasive continuous positive airway pressure 
  
 
Figure 4S Cumulative incidence of in-hospital mortality stratified by number of CPAP days among 




Cumulative incidence at 60 days – CPAP days ≤3: 0.350 (0.259-0.441). 
Cumulative incidence at 60 days – CPAP  days >3: 0.510 (0.393-0.615). 













































CPAP, noninvasive continuous positive airway pressure 
 Overall (n= 537) 
Characteristic, number of observations  
Age 537 
Male 537 
Body mass index 239 
White blood cell count 533 




C-reactive protein 509 
Ferritin 223 
Lactate dehydrogenase 454 
D-dimer 192 
Charlson Comorbidity index 537 
Chronic arterial hypertension 537 
Diabetes 537 
Ischaemic heart disease 537 
CPAP 537 
Hospital length of stay 537 
 









































e range) or number (percentage). p values were calculated by Mann-Whitney U test or χ
2
 test, as appropriate 
 PaO2/FiO2 > 300 300 ≥ PaO2/FiO2 < 200 200 ≥ PaO2/FiO2 >100 PaO2/FiO2 ≤ 100 
 177 (33) 75 (14) 195 (36) 90 (17) 
Characteristics     
Age, years 
a 
69 (59-76) 66 (59-73) 68 (60-75) 72 (65-79) 
Male, n (%) 128 (72) 53 (71) 146 (75) 64 (71) 
Body mass index, kg/m
2
 28 (25-31) 27 (25-31) 28 (25-31) 28 (23-31) 
White blood cell count, x10
3
/L 




a 0.9 (0.6-1.2) 0.8 (0.6-1.2) 0.9 (0.6-1.1) 0.7 (0.5-1.0) 
Creatinine, mg/dL 
a 
1.0 (0.8-1.2) 0.9 (0.7-1.2) 0.9 (0.8-1.3) 1.1 (0.8-1.6) 
Aspartate-aminotransferase, U/L 40 (26-59) 38 (27-48) 42 (30-61) 43 (33-70) 
Alanine-aminotransferase, U/L 34 (21-51) 31 (22-50) 33 (23-50) 34 (21-51) 
C-reactive protein, mg/dL 13 (7-20) 10 (4-15) 11 (6-18) 13 (7-20) 
Ferritin, ng/mL 
a 
802 (430-1545) 1177 (600-1879) 1143 (621-1679) 1222 (931-1697) 
Lactate dehydrogenase, U/L 575 (446-732) 544 (422-759) 597 (383-840) 510 (405-754) 
D-dimer, gFEU/L 931 (525-1730) 1294 (522-1990) 897 (549-2008) 987 (483-2190) 
Charlson comorbidity index
 
1 (0-2) 1 (0-2) 1 (0-2) 1 (0-2) 
Chronic arterial hypertension, n (%) 88 (50) 31 (41) 103 (53) 56 (62) 
Diabetes, n (%) 44 (25) 14 (19) 55 (28) 25 (28) 
Ischaemic heart disease, n (%) 23 (13) 11 (15) 20 (10) 12 (13) 
CPAP, days 
a 
6 (3-9) 5 (3-9) 4 (1-9) 1 (1-6) 
Hospital length of stay, days
 
14 (6-27) 16 (10-27) 17 (8-30) 14 (6-27) 
 
CPAP, noninvasive continuous positive airway pressure; FEU, fibrinogen-equivalent unit. 
a
Kruskal-Wallis p < 0.05
 
Table 3S General characteristics of patients according to CPAP interface applied 
Values are median (interquartile range) or number (percentage). 
CPAP, noninvasive continuous positive airway pressure; ICU, intensive care unit; FEU, fibrinogen-equivalent unit 
Helmet vs. mask: 
*
 p =0.030, † p=0.002, § p=0.001, °p<0.0001, ‡ p=0.032.
 Helmet (n=399) Mask (n=123) Mask and Helmet (n=15) 
Characteristics    
Age, years 68 (58-74) 71 (64-78)
*
 75 (71-82) 
Male, n (%) 292 (73) 86 (70) 13 (87) 
Body mass index, kg/m
2
 28 (25-31) 28 (25-30) 28 (27-29) 
White blood cell count, x10
3
/L 6.7 (5.1-9.0) 8.0 (5.1-10.5)† 7.1 (4.5-10.6) 
Lymphocyte count, x10
3
/L 0.8 (0.6-1.2) 0.7 (0.5-1.0)
§
 0.6 (0.5-0.8) 
Creatinine, mg/dL 0.9 (0.8-1.2) 1.0 (0.8-1.4) 1.0 (0.8-1.3) 
Aspartate-aminotransferase, U/L 41 (29-54) 46 (30-70) 59 (30-89) 
Alanine-aminotransferase, U/L 32 (22-50) 31 (23-47) 38 (26-82) 
C-reactive protein, mg/dL 11 (5-17) 12 (8-18) 11 (6-23) 
Ferritin, ng/mL 1053 (572-1662) 1012 (480-1310) 1434 (518-1697) 
Lactate dehydrogenase, U/L 616 (450-808) 448 (318-606)° 470 (314-482) 
D-dimer, gFEU/L 1050 (579-1951) 677 (426-1603)‡ 1320 (1169-2576) 
Charlson comorbidity index
 
1 (0-2) 1 (0-2) 1 (0-2) 
Chronic arterial hypertension, n (%) 207 (52) 58 (47)
 
13 (87) 
Diabetes, n (%) 106 (27) 25 (20) 7 (47) 
Ischaemic heart disease, n (%) 45 (11) 20 (16) 1 (7) 
CPAP, days
 
4 (2-8) 3 (1-9) 7 (2-13) 
Hospital length of stay, days
 
16 (9-27) 17 (11-27) 13 (8-35) 
 
Table 4S Number of observations for each variable 
 Full treatment (n=397) Do-not-intubate (n=140) 
Characteristic, number of observations   
Age 397 140 
Male 397 140 
Body mass index 196 43 
White blood cell count 395 138 
Lymphocyte count 392 137 
Creatinine 394 137 
Aspartate-aminotransferase 248 87 
Alanine-aminotransferase 371 132 
C-reactive protein 377 132 
Ferritin 180 43 
Lactate dehydrogenase 345 109 
D-dimer 150 42 
Charlson Comorbidity index 397 140 
Chronic arterial hypertension 397 140 
Diabetes 397 140 
Ischaemic heart disease 397 140 
Cancer 397 140 
CPAP 397 140 
Hospital length of stay 397 140 
CPAP, noninvasive continuous positive airway pressure
 





































ABG, arterial blood gas analysis; CPAP, noninvasive continuous positive airway pressure; PaCO2, arterial partial 
pressure of carbon dioxide; PaO2, arterial partial pressure of oxygen; SpO2, peripheral oxygen saturation; HCO
3-
, 
bicarbonate; FiO2, inspired oxygen fraction; PaO2/FiO2, arterial partial pressure of oxygen to inspired oxygen fraction 
ratio; SpO2/FiO2, peripheral oxygen saturation to inspired oxygen fraction ratio 
a
Arterial blood gas analysis performed before CPAP initiation 
b
First arterial blood gas analysis performed 2-24 hours after CPAP outset 
†
Mann Whitney U test p < 0.01 full treatment vs. do not intubate 
*
Wilcoxon signed-rank test p < 0.01 ABG before CPAP vs. ABG after CPAP 
  
 Overall (n=537) Full treatment (n=397) Do not intubate (n=140) 
ABG before CPAP
a 
   
pH 7.47 (7.43-7.49) 7.47 (7.44-7.49)† 7.46 (7.42-7.48) 
PaCO2, mmHg 35 (31-38) 35 (31-38) 34 (31-37) 
PaO2, mmHg 60 (49-73) 60 (51-73)† 54 (46-68) 





25 (23-27) 26 (23-28)† 24 (22-26) 
Lactate, mmol/L 1.2 (0.9-1.7) 1.2 (0.9-1.6) 1.2 (1.0-1.7) 
FiO2, % 50 (50-100) 50 (50-100) 50 (50-100) 
PaO2/FiO2, mmHg 108 (71-157) 115 (73-158) 94 (66-146) 
SpO2/FiO2, % 164 (95-194) 171 (96-194) 161 (94-190) 
Respiratory Rate, breaths/min 27 (22-32) 26 (22-32) 28 (24-32) 
ABG after CPAP
b 
   
pH 7.45 (7.42-7.48) 7.45 (7.42-7.48)†* 7.43 (7.40-7.46)* 
PaCO2, mmHg 36 (33-40) 36 (33-40)* 36 (32-41)* 
PaO2, mmHg 85 (60-132) 87 (62-135)* 75 (56-126)* 
SpO2, % 96 (91-98) 96 (92-98)†* 94 (90-98)* 
HCO3
-
, mmol/L 26 (23-28) 26 (24-28)† 25 (21-28) 
Lactate, mmol/L 1.2 (0.9-1.6) 1.1 (0.8-1.6)†* 1.4 (1.0-1.7) 
FiO2, % 50 (50-60) 50 (50-60)* 50 (50-60)* 
PaO2/FiO2, mmHg 157 (109-255) 162 (109-259)* 148 (105-232)* 
SpO2/FiO2, % 176 (153-196) 176 (152-196)* 180 (157-196)* 
Respiratory Rate, breaths/min 24 (20-28) 24 (20-28)* 25 (21-28)* 
































Abbreviations: ABG, arterial blood gas analysis; CPAP, noninvasive continuous positive airway pressure; PaCO2, 
arterial partial pressure of carbon dioxide; PaO2, arterial partial pressure of oxygen; SpO2, peripheral oxygen 
saturation; HCO
3-
, bicarbonate; FiO2, inspired oxygen fraction; PaO2/FiO2, arterial partial pressure of oxygen to 
inspired oxygen fraction ratio; SpO2/FiO2, peripheral oxygen saturation to inspired oxygen fraction ratio 
a
Arterial blood gas analysis performed before CPAP initiation 
b
First arterial blood gas analysis performed 2-24 hours after CPAP outset 
 
 
 Overall (n= 537) Full treatment (n=397) Do not intubate (n=140) 
ABG before CPAP
a 
   
pH 492 370 122 
PaCO2 493 371 122 
PaO2 497 374 123 
SpO2 535 395 140 
HCO3
-  
484 365 119 
Lactate 434 329 105 
FiO2 409 307 102 
PaO2/FiO2 383 290 93 
SpO2/FiO2 408 306 102 
Respiratory Rate 351 258 93 
ABG after CPAP
b 
   
pH 462 353 109 
PaCO2 462 352 110 
PaO2 466 356 110 
SpO2 534 395 139 
HCO3
-
 456 347 109 
Lactate 392 299 93 
FiO2 499 376 102 
PaO2/FiO2 443 344 99 
SpO2/FiO2 499 376 123 
Respiratory Rate 348 257 91 








Table 7S Fine and Gray model for the association between CPAP treatment duration and mortality after the 
application of multiple imputation procedure. 
 
  sHR 95%CI 
CPAP, days 1.060 (1.001-1.121) 
Male 1.229 (0.668-2.261) 
Age 1.037 (1.002-1.073) 
Hypertension, yes vs. no 1.075 (0.671-1.722) 
Charlson index 1.260 (1.049-1.515) 
Lactate dehydrogenase, U/L 1.000 (0.999-1.001) 
C-reactive protein, mg/dL 0.996 (0.963-1.030) 
Lymphocytes, x10
3
/mL 1.323 (0.854-2.049) 
 
Abbreviations: CPAP, continuous positive airway pressure; sHR, sub-distribution hazard ratio; 95% CI; 95% confidence interval. 
Sub-distribution hazard ratio and 95% corresponding confidence interval deriving from the multivariate Fine and Gray models. 
Estimates are further adjusted by center. N:180 
 
